Compare Fresenius Kabi Onco. with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ABBOTT INDIA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ABBOTT INDIA FRESENIUS KABI ONCO./
ABBOTT INDIA
 
P/E (TTM) x 22.1 50.5 43.8% View Chart
P/BV x 3.1 16.3 19.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   ABBOTT INDIA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA
Mar-19
FRESENIUS KABI ONCO./
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1768,834 2.0%   
Low Rs795,458 1.4%   
Sales per share (Unadj.) Rs37.71,731.1 2.2%  
Earnings per share (Unadj.) Rs5.1211.9 2.4%  
Cash flow per share (Unadj.) Rs6.7219.9 3.1%  
Dividends per share (Unadj.) Rs065.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs42.5945.2 4.5%  
Shares outstanding (eoy) m158.2321.25 744.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.1 81.8%   
Avg P/E ratio x25.033.7 74.1%  
P/CF ratio (eoy) x18.932.5 58.2%  
Price / Book Value ratio x3.07.6 39.6%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m20,135151,848 13.3%   
No. of employees `0001.23.5 33.1%   
Total wages/salary Rs m7034,356 16.1%   
Avg. sales/employee Rs Th5,176.210,555.5 49.0%   
Avg. wages/employee Rs Th610.41,249.9 48.8%   
Avg. net profit/employee Rs Th699.61,292.2 54.1%   
INCOME DATA
Net Sales Rs m5,96336,786 16.2%  
Other income Rs m181,133 1.6%   
Total revenues Rs m5,98137,919 15.8%   
Gross profit Rs m1,4306,047 23.6%  
Depreciation Rs m258169 152.4%   
Interest Rs m-2623 -115.6%   
Profit before tax Rs m1,2166,989 17.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,485 13.8%   
Profit after tax Rs m8064,503 17.9%  
Gross profit margin %24.016.4 145.9%  
Effective tax rate %28.135.6 79.1%   
Net profit margin %13.512.2 110.4%  
BALANCE SHEET DATA
Current assets Rs m5,10227,610 18.5%   
Current liabilities Rs m2,3858,569 27.8%   
Net working cap to sales %45.651.8 88.0%  
Current ratio x2.13.2 66.4%  
Inventory Days Days15060 249.2%  
Debtors Days Days11327 413.5%  
Net fixed assets Rs m5,1481,057 487.1%   
Share capital Rs m158213 74.4%   
"Free" reserves Rs m6,55619,873 33.0%   
Net worth Rs m6,73220,086 33.5%   
Long term debt Rs m9520-   
Total assets Rs m10,38829,409 35.3%  
Interest coverage x-45.8311.6 -14.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.3 45.9%   
Return on assets %7.515.4 48.8%  
Return on equity %12.022.4 53.4%  
Return on capital %14.634.9 41.8%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298369 1,435.8%   
Fx outflow Rs m1,7724,918 36.0%   
Net fx Rs m3,525-4,549 -77.5%   
CASH FLOW
From Operations Rs m1,2744,991 25.5%  
From Investments Rs m-1,204-2,570 46.9%  
From Financial Activity Rs m-196-1,428 13.7%  
Net Cashflow Rs m-126993 -12.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 9.6 0.1 9,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   42,599 18,270 233.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ELDER PHARMA  FDC  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher, Dow Futures Up by 53 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 191 points, up 0.4% at 48,868 levels.

Related Views on News

J.B.CHEMICALS at All Time High; BSE HEALTHCARE Index Up 0.2% (Market Updates)

May 6, 2021 | Updated on May 6, 2021

J.B.CHEMICALS share price has hit an all time high at Rs 1,460 (up 2.8%). The BSE HEALTHCARE Index is up by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are J.B.CHEMICALS (up 2.8%) and ABBOTT INDIA (up 0.5%). The top losers include IPCA LABS and DIVIS LABORATORIES .

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS